Patent ID: 7524872
Filing Date: 2009-04-28
Classification: A61K

Abstract:
1. A method for inhibiting tumor growth comprising: a) administering directly to a tumor site in a mammal an effective amount of an organelle and cytoskeleton crystallizing agent, wherein said crystallizing agent is selected from the group consisting of p-Anisyl Blue Tetrazolium Chloride, p-Anisyl-p-Nitro Blue Tetrazolium Chloride, Thiazolyl blue, 2-2′-Benzothiazolyl-5-styryl-3-(4-phthalhydrazidyl) tetrazolium chloride), Blue tetrazolium chloride, 2-(2′-Benzothiazolyl)-5-styryl-3-(4′-phthalhydrazidyl)-tetrazolium chloride, 5-Cyano-2,3-ditolyl tetrazolium chloride, 1-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide, Distyryl nitroblue tetrazolium chloride, (1H)-tetrazole, Iodonitrotetrazolium chloride, Iodo Nitro Tetrazolium Violet Chloride, p-iodo nitrotetrazolium violet, (2-(4-iodophenyl)-3-(4-nitrophenyl)-5-phenyltetrazolium chloride, 2-(p-iodophenyl)-p-nitrophenyl-5-phenyltetrazolium chloride, m-Nitro Blue Tetrazolium Chloride, m-Nitro Neotetrazolium Chloride, 2,2-bis(2-methoxyl-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt, tetrazolium bromide, thiazolyl blue tetrazolium bromide, (3→4,5-dimethylthiazol-2-yl-2,5-diphenyltetrazolium bromide), Nitro Blue Monotetrazolium Chloride, p-Nitro Blue Tetrazolium Chloride, (2,2′-di-nitrophenyl-5,5′-diphenyl-3,3′-(3,3′-dimethoxy-4,4′-diphenylene ditetrazolium chloride), Neotetrazolium chloride (2,2′,5,5′-Tetraphenyl-3,3′(p-diphenylene))-ditetrazolium chloride, Nitrotetrazolium Violet, Thiazolyl blue, tetrazolium blue chloride (3,3′→3,3′-dimethoxy(1,1′-biphenyl)-4,4′-diyl]-bis(2,5-diphenyl-2H-tetrazolium)dichloride), o-Tolyl Tetrazolium Red, sodium 3′-[1-[(phenylamino)-carbonyl]-3,4-tetrazolium]-bis(4-methoxy-6-nitro)benzene-sulfonic acid hydrate, Piperonyl Tetrazolium Blue, p-Tolyl Tetrazolium Red, Thiocarbamyl nitro blue tetrazolium chloride, 2,2′-di-p-nitrophenyl-5,5′-di-p-thiocarbamylphenyl-3,3′[3,3′-dimethoxy-4,4′-biphenylene]-ditetrazolium chloride, Tetranitroblue tetrazolium chloride, 1,3,5-triphenyltetrazolium, Tetrazolium Red, 2,3,5-triphenyltetrazolium chloride, Tetrazolium violet, 2,3,5-Triphenyl-2-H-tetrazolium chloride, 2,5-diphenyl-3-[α-naphthyl]-tetrazolium chloride, 2,5-diphenyl-3-[1-naphthyl]-2H-tetrazolium chloride, Veratryl tetrazolium blue, 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate, and 2,2-bis(2-methoxyl-4-notro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide, and wherein said crystallizing agent forms crystals in an organelle and/or cytoskeleton of tumor cells through a reaction catalyzed by cellular enzymes; and, b) administering to said mammal an effective amount of a chemotherapeutic agent selected from the group consisting of acalacinomycin, alitretinoin, allopurinol, altretamine, anastrozole, arsenic trioxide, asparaginase, busulfan, calusterone, camptothecin, capecitabine, carmofur, cladribine, dacarbazine, dexrazoxane, docetaxel, doxifloridine, doxorubicin, dromostanolone, epirubicin, estramustine, etoposide, exemestane, floxuridine, fludarabine, fluorouracil, fulvestrant, gemcitabine, homoharringtonine, hydroxycamptothecin, hydroxyurea, irinotecan, letrozole, levamisole, mesna, mitotane, mitoxantrone, oxaliplatin, paclitaxel, pipobroman, pirarubicin, Sarmustine, semustine, tamoxifen, tegafur-uracil, temozotomide, teniposide, testolactone, thioguanine, thiotepa, topotecan, valrubicin, vinblastine, vincristine, vindesine, and vinorelbine.